Tirzepatide, known commercially as Mounjaro and Zepbound, may activate calorie-burning brown fat in addition to suppressing appetite. This finding comes from a mouse study. The research suggests a new mechanism for the drug's effects on metabolism.
The study, conducted by the University of Barcelona, investigated how tirzepatide affects different fat deposits in obese mice. Researchers compared mice treated with tirzepatide to a control group. The control group received the same amount of food but no drug. This method helped isolate the drug's direct metabolic effects from those caused by reduced food intake.
Brown adipose tissue, or brown fat, specializes in burning calories for energy. White adipose tissue, in contrast, stores fat. The analysis showed that tirzepatide activated brown fat in the treated mice. This activation increased the capacity to burn metabolic energy. It also led to the production of beneficial molecules called batokines.
This suggests tirzepatide influences metabolism beyond appetite suppression. Activating brown fat helps burn glucose and fat within the body. This contributes to weight reduction and improved blood glucose and fat levels. The drug also showed cardiovascular benefits in the study.
Activating brown fat has long been a goal for treating obesity. Previous attempts often caused unwanted side effects, particularly affecting the heart. Tirzepatide activated brown fat without these negative effects. This indicates a potential for more comprehensive obesity treatments. These treatments could focus on both reducing food intake and increasing energy expenditure.
However, the findings are from a mouse study. Human and mouse metabolism can differ significantly. More clinical evidence is needed to confirm these effects in people. This research could lead to more personalized medicine for obesity and metabolic disorders.
Related stories
Experimental Compound Burns Fat Without Muscle Loss in Mice
An experimental compound called TOFA helped obese mice burn fat, preserve muscle, and improve metabolic health, offering a new approach to obesity treatment.
New Drug Shows Promise for Obesity and Type 2 Diabetes
A new "Trojan horse" drug for obesity and type two diabetes shows promise in mouse studies, delivering a metabolic enhancer directly to cells for improved weight loss and blood sugar control.
Semaglutide May Slow Aging in Mice, Extend Lifespan
A new study suggests semaglutide, found in Ozempic and Wegovy, may slow aging and extend lifespan in mice by impacting biological mechanisms beyond calorie restriction.